RhoA/ROCK Pathway Inhibitor Ameliorates Radiation-induced Erectile Dysfunction in Rats

Localized prostate cancer (PCa) has a high cure rate of 95.5%. PCa patients receive radiation therapy (RT) as a standard of care treatment. However, the major concern is the treatment-related side effects compromising the quality of life (QoL) in PCa patients. Radiation-induced Erectile Dysfunction (RiED) is a common and irreversible late side effect of RT, that develops in more than half of PCa patients. There is no FDA approved drug to treat RiED. Phosphodiesterase type 5 inhibitors (PDE5i) are the most common pharmacological agents being used to treat RiED.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research

Related Links:

Medical device companies attempting to market a new treatment in the U.S. often make the erroneous assumption that winning FDA approval is the final destination, and success is theirs. In fact, going through the regulatory process is only the halfway point. The grueling path from FDA approval to reimbursement is like a treacherous walk through Death Valley and many companies don’t make it through. In this case study, I discuss the trials and triumphs of bringing robotic high intensity focused ultrasound (HIFU), a non-invasive procedure for localized prostate cancer, to the U.S.&Aci...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Business Source Type: news
CONCLUSION: Hemiablation HIFU is an alternative to whole gland therapy in patients with unilateral radio- recurrent prostate cancer, which offers limited urinary and rectal morbidity, and preserves functional outcomes. LEVEL OF EVIDENCE: 3. PMID: 31400963 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
To assess whether BIO 300, a synthetic genistein nanosuspension, improves the therapeutic index in prostate cancer treatment by preventing radiation-induced erectile dysfunction (ED) without reducing tumor radiosensitivity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Radiation induced erectile dysfunction (RiED) remains a significant problem for patients undergoing radiation therapy (RT) for prostate cancer. SpaceOAR (Augmenix, Boston MA) hydrogel is placed in the rectoprostatic space to displace the prostate from the rectum and has demonstrated to reduce rectal toxicity. SpaceOAR hydrogel patients receiving EBRT were also more likely to preserve sexual function in a phase III trial. While the proposed mechanism of this improvement was via lower mean radiation doses to the penile bulb, both groups of patients received RT doses below the published dose-tolerances of this structure.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Erectile Dysfunction, CTCAE;   Impotence;   Prostate Adenocarcinoma Interventions:   Drug: Atorvastatin;   Drug: Pentoxifylline;   Dietary Supplement: Vitamin E Compound Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Radiation-induced erectile dysfunction (RI-ED) following prostate cancer radiation therapy is a significant survivorship problem. The etiology of this condition has been postulated to result from injury to the penile vessels, nerves or both. To address this gap in knowledge, we applied a vascular radioprotectant to a rat model of RI-ED. Protecting the vasculature did not improve erectile function or prevent nerve injury, suggesting a critical role for RT-mediated nerve damage in RI-ED.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Biology Contribution Source Type: research
AbstractRecent studies have examined the impact of phosphodiesterase type 5 inhibitors (PDE5 ‐Is) use on the risk of prostate cancer, and biochemical recurrence (BCR) in prostate cancer patients, but the results were inconsistent. A meta‐analysis was conducted to assess the associations with all published studies. Databases (PubMed, Web of Science and MEDLINE) were retrieved to identify relevant studies which explored the impact of PDE5‐Is use on the risk of prostate cancer, and BCR in prostate cancer patients. The summary results along with 95% confidence intervals (CIs) were calculated. Nine articles were eligible ...
Source: Andrologia - Category: Urology & Nephrology Authors: Tags: INVITED REVIEW Source Type: research
Authors: Sussman R, Carvalho FLF, Harbin A, Zheng C, Lynch JH, Stamatakis L, Hwang J, Williams SB, Hu JC, Kowalczyk KJ Abstract INTRODUCTION: The utility of radical prostatectomy (RP) for locally-advanced prostate cancer remains unknown. Retrospective data has shown equivalent oncologic outcomes compared to radiation therapy (RT). RP may provide local tumor control and prevent secondary interventions from local invasion, and may decrease costs. MATERIALS AND METHODS: Using SEER-Medicare data from 1995-2011 we identified men with locally-advanced prostate cancer undergoing RP or RT. Rates of post-treatment diagn...
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research
Publication date: 2014Source: Yearbook of Urology, Volume 2014Author(s): A.W. Shindel
Source: Yearbook of Urology - Category: Urology & Nephrology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Erectile Dysfunction | Physics | Prostate Cancer | Radiation Therapy | Radiology